Welcome to our dedicated page for Perceptive Cap news (Ticker: PCSC), a resource for investors and traders seeking the latest updates and insights on Perceptive Cap stock.
Perceptive Capital Solutions Corp (PCSC) is a Nasdaq-listed special purpose acquisition company in the Financial Services sector, categorized as a shell company. Public communications describe PCSC as a blank check company formed to enter into a combination with one or more businesses or entities, with an intended focus on the healthcare industry in the United States and other developed countries.
This news page aggregates coverage related to PCSC’s capital markets activity and its announced plans for a business combination. One key theme in recent announcements is the definitive business combination agreement between Perceptive Capital Solutions Corp and Freenome Holdings, Inc., an early cancer detection company developing blood-based screening tests. News items describe how, upon closing of the transaction, PCSC is expected to redomicile as a Delaware corporation, be renamed Freenome, Inc., and have its common stock listed on Nasdaq under the ticker symbol FRNM, subject to approvals and other conditions.
Readers can review articles detailing the initial public offering of PCSC’s Class A ordinary shares on The Nasdaq Global Market, including information about the offering price, the role of Jefferies LLC as sole book-running manager, and the company’s stated intention to focus on healthcare-related business combinations. Additional coverage discusses the structure of the proposed transaction with Freenome, including the trust account held by PCSC and the concurrent private investment in public equity (PIPE) led by Perceptive Advisors and RA Capital.
By following PCSC-related news, investors and observers can track developments around its SPAC lifecycle, from the initial public offering through the negotiation and proposed completion of a business combination. This includes updates on shareholder approvals, regulatory filings, transaction terms and other disclosures that shape the future of the PCSC ticker and any resulting combined company.
Freenome (Nasdaq: PCSC) entered a definitive business combination to become a publicly listed company expected to trade as FRNM on Nasdaq following closing, targeted for the first half of 2026. The deal includes a $240 million common equity PIPE at $10.00 per share led by Perceptive Advisors and RA Capital, plus approximately $90 million in PCSC trust funds, providing roughly $330 million of proceeds (assuming no redemptions).
The combined company is expected to have a post-transaction equity value of about $1.1 billion. Freenome shareholders will roll 100% of their equity into the Combined Company. The proceeds are intended to accelerate Freenome's AI/ML multiomics platform, commercial scale-up for multiple 2026 test launches, and pipeline advancement; commercial partners include Exact Sciences and Roche.
Perceptive Capital Solutions Corp (PCSC), a special purpose acquisition company, has announced the pricing of its $75 million initial public offering. The offering consists of 7,500,000 Class A ordinary shares at $10.00 per share, with trading set to begin on the Nasdaq Global Market under the ticker "PCSC" on June 12, 2024. The company is targeting the healthcare industry for its business combination. The underwriters, led by Jefferies , have a 45-day option to purchase an additional 1,125,000 shares. The offering is expected to close on June 13, 2024, pending standard closing conditions.